These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27692620)

  • 1. Solubility Advantage (and Disadvantage) of Pharmaceutical Amorphous Solid Dispersions.
    Huang S; Mao C; Williams RO; Yang CY
    J Pharm Sci; 2016 Dec; 105(12):3549-3561. PubMed ID: 27692620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicted amorphous solubility and dissolution rate advantages following moisture sorption: Case studies of indomethacin and felodipine.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Jan; 555():100-108. PubMed ID: 30448307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
    Sun DD; Ju TC; Lee PI
    Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
    Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects.
    Prasad D; Chauhan H; Atef E
    J Pharm Sci; 2014 Nov; 103(11):3511-3523. PubMed ID: 25196860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailoring supersaturation from amorphous solid dispersions.
    Li N; Taylor LS
    J Control Release; 2018 Jun; 279():114-125. PubMed ID: 29654798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
    Sun DD; Lee PI
    J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
    Luebbert C; Wessner M; Sadowski G
    Mol Pharm; 2018 Feb; 15(2):669-678. PubMed ID: 29309155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance.
    Chen H; Pui Y; Liu C; Chen Z; Su CC; Hageman M; Hussain M; Haskell R; Stefanski K; Foster K; Gudmundsson O; Qian F
    J Pharm Sci; 2018 Jan; 107(1):317-326. PubMed ID: 29107047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions.
    Xiang TX; Anderson BD
    J Pharm Sci; 2013 Mar; 102(3):876-91. PubMed ID: 23280486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation and correlation of physical stability, dissolution behaviour and interaction parameter of amorphous solid dispersions of telmisartan: a drug development perspective.
    Dukeck R; Sieger P; Karmwar P
    Eur J Pharm Sci; 2013 Jul; 49(4):723-31. PubMed ID: 23684913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solubility advantage from amorphous etoricoxib solid dispersions.
    Dani P; Puri V; Bansal AK
    Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions.
    Chen Y; Liu C; Chen Z; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
    Mol Pharm; 2015 Feb; 12(2):576-89. PubMed ID: 25535667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers.
    Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
    Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
    Fini A; Cavallari C; Ospitali F
    Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.
    Sun DD; Lee PI
    Mol Pharm; 2015 Apr; 12(4):1203-15. PubMed ID: 25775257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Eudragit EPO and hydroxypropyl methylcellulose on drug release rate, supersaturation, precipitation outcome and redissolution rate of indomethacin amorphous solid dispersions.
    Xie T; Gao W; Taylor LS
    Int J Pharm; 2017 Oct; 531(1):313-323. PubMed ID: 28844901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of the thermal phase diagram of amorphous solid dispersions by Flory-Huggins theory.
    Zhao Y; Inbar P; Chokshi HP; Malick AW; Choi DS
    J Pharm Sci; 2011 Aug; 100(8):3196-3207. PubMed ID: 21416468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissolution and precipitation behavior of amorphous solid dispersions.
    Alonzo DE; Gao Y; Zhou D; Mo H; Zhang GGZ; Taylor LS
    J Pharm Sci; 2011 Aug; 100(8):3316-3331. PubMed ID: 21607951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.